Blume Gustavo Gavazzoni, Machado-Júnior Paulo André Bispo, Paludo Bertinato Giovana, Simeoni Rossana Baggio, Francisco Julio César, Guarita-Souza Luiz César
Division of Cardiovascular Diseases, School of Medicine, Catholic University Curitiba, Paraná, Brazil.
Am J Cardiovasc Dis. 2021 Feb 15;11(1):1-11. eCollection 2021.
myocardial infarction (MI) remains the leading cause of death worldwide. Cell-based therapies have become potential therapeutic approaches, attempting to recover the contractility of necrotic cardiomyocytes. In the present study, we aimed to systematically evaluate experimental studies on the use of tissue-engineered amniotic membrane (hAMC) in MI treatment.
a systematic review of literature published in PubMed, Embase and CENTRAL databases was conducted, until March 31, 2020, for experimental studies reporting on hAMC cell-therapy performed on LV function, MI size, paracrine effects, angiogenesis, and cell differentiation. Two reviewers selected the articles that met the inclusion criteria and disagreements were solved through a consensus.
a total of 11 studies were included for data extraction. For the acute scenario, therapeutic use of hAMC after MI was capable of improving LV function in rats, mainly due to its paracrine effects (anti-apoptotic and anti-inflammatory) and associated with cardiomyocyte differentiation, MI size reduction and neo-angiogenesis.
tissue engineered hAMC following MI provided clinically relevant benefits on cardiac function and ventricular remodeling.
心肌梗死(MI)仍是全球主要的死亡原因。基于细胞的疗法已成为潜在的治疗方法,试图恢复坏死心肌细胞的收缩力。在本研究中,我们旨在系统评价关于使用组织工程羊膜(hAMC)治疗MI的实验研究。
对PubMed、Embase和CENTRAL数据库中截至2020年3月31日发表的文献进行系统综述,纳入关于hAMC细胞治疗对左心室功能、MI面积、旁分泌作用、血管生成和细胞分化影响的实验研究。两名评审员筛选符合纳入标准的文章,分歧通过协商解决。
共纳入11项研究进行数据提取。在急性情况下,MI后使用hAMC进行治疗能够改善大鼠的左心室功能,主要归因于其旁分泌作用(抗凋亡和抗炎),并与心肌细胞分化、MI面积缩小和新生血管形成有关。
MI后组织工程化hAMC对心脏功能和心室重构具有临床相关益处。